

Basal Ganglia Changes Predict Psychiatric Lupus

BY DAMIAN McNAMARA
Miami Bureau

BIRMINGHAM, ENGLAND — Metabolic changes in the basal ganglia that can be detected with magnetic resonance spectroscopy may precede irreversible changes from neuropsychiatric lupus, according to a pilot study.

“Why look at basal ganglia? They are highly prone to hypoxic damage and have recently been linked with the frontal lobe regarding cognitive function,” Dr. Pamela L. Peterson said at the annual meeting of the British Society for Rheumatology. In Parkinson disease “and other diseases, there is increasing recognition of the role of basal ganglia.”

There are at least four circuits that link the basal ganglia to the cerebral cortex. Although less common, movement disorders are a well-accepted complication of neu-

Though pilot data included only magnetic resonance spectrometry findings, changes in myoinositol in these two regions also appear to be correlated.

ropsychiatric systemic lupus erythematosus (NPSLE) and may be mediated by the basal ganglia, said Dr. Peterson, a rheumatology fellow at St. George’s Hospital, London.

Clinicians more commonly order MRIs to detect abnor-

malities in the periventricular region and subcortical white matter of patients with NPSLE. However, magnetic resonance spectroscopy of the basal ganglia might prove useful for earlier clinical intervention.

“Magnetic resonance spectroscopy is noninvasive, cheap, and easily added to an MRI protocol,” Dr. Peterson said.

Preliminary findings of the study are based on 24 patients with NPSLE, 8 patients with active lupus but without neurologic symptoms, and 4 healthy controls. Participants are recruited for the ongoing study from St. George’s University of London; St. Thomas’ Hospital, London; and University College London. The age range is 17-54 years.

Blood tests indicated absolute concentrations of *N*-acetylaspartate (NAA), choline, creatine, and myoinositol. The metabolite NAA is a marker for neuronal

loss or dysfunction, Dr. Peterson said. Participants had an MRI, magnetic resonance spectroscopy, and diffusion tensor imaging, plus an interview, clinical assessment, and psychometric testing.

The researchers found a statistically significant correlation between decreases in NAA in the basal ganglia and frontal white matter. Also, levels were significantly lower in these regions, compared with healthy controls. “There was a stepwise deterioration in NAA with worsen-

ing neurologic effects,” Dr. Peterson said.

Participants with non-neuropsychiatric lupus also had decreases in the metabolite, but the reductions were not significantly different, compared with controls.

“This correlation may simply indicate a global reduction of NAA in patients with NPSLE or it may reflect abnormalities in the circuits connecting the frontal white matter with the basal ganglia,” the researchers noted. NPSLE may alter the cortical striatal fibers that connect basal gan-

glia and frontal lobe, Dr. Peterson added.

Although the pilot data from the study included only magnetic resonance spectroscopy findings, Dr. Peterson said changes in myoinositol in these two regions also appear to be correlated. In addition, initial psychometry results suggest “a possible relationship between NAA reduction in the basal ganglia and processing speed.”

“My results are tentative. This is a small data set,” Dr. Peterson said. “We want bigger numbers in the future.” ■

Help shape the future of atrial fibrillation

Be a part of the search for a new approach to anticoagulation

ROCKET AF



Patients with nonvalvular atrial fibrillation are now enrolling in a new clinical trial to compare the efficacy and safety of an oral, direct Factor Xa inhibitor with that of standard warfarin therapy (INR target 2.5, range 2.0-3.0 inclusive).

Eligibility

Male or nonpregnant female, aged ≥ 18 years with nonvalvular atrial fibrillation with either:

- ◆ History of stroke, transient ischemic attack (TIA), or non-CNS systemic embolism (presumed to be cardioembolic in nature) **or**
- ◆ 2 or more of the following risk factors: hypertension, heart failure, diabetes mellitus, aged ≥ 75 years

Ineligibility

- ◆ Contraindication to anticoagulant therapy
- ◆ Prosthetic heart valve
- ◆ History of, or condition associated with, increased risk of hemorrhage



Get involved in the investigation

For more information, please e-mail us at rocket-af@mc.duke.edu

To learn more, visit www.clinicaltrials.gov, identifier NCT00403767.

 Duke Clinical Research Institute

Sponsored by  Bayer HealthCare in collaboration with  Johnson & Johnson
PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C.

Progress Report on Alzheimer Disease

The National Institute on Aging’s Alzheimer’s Disease Education and Referral (ADEAR) Center has published the “2005-2006 Progress Report on Alzheimer’s Disease: Journey to Discovery.” The 64-page report, which describes advances in discovering the causes and processes of cognitive decline, is available free from the ADEAR Center at 800-438-4380 and can be previewed online at www.nia.nih.gov/Alzheimers/Publications/ADProgress2005_2006. ■